EXCLUSIVE: Three medicinal cannabis products publicly named by the Therapeutic Goods Administration as having failed to comply with required standards have been exonerated by third party analysis in a development that will increase pressure to produce standardised lab testing across Australia.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

The disparity in test results will also concern the TGA which in September stated that five products were found to be stronger or weaker than permitted under Therapeutic Goods Order 93 (TGO93) regulations.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...